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Abstract
Human vaccinia-related kinases (VRK1 and VRK2) are atypical active Ser-Thr kinases implicated in control of cell cycle entry,
apoptosis and autophagy, and affect signalling by mitogen activated protein kinases (MAPK). The specific structural
differences in VRK catalytic sites make them suitable candidates for development of specific inhibitors. In this work we have
determined the sensitivity of VRK1 and VRK2 to kinase inhibitors, currently used in biological assays or in preclinical studies,
in order to discriminate between the two proteins as well as with respect to the vaccinia virus B1R kinase. Both VRK proteins
and vaccinia B1R are poorly inhibited by inhibitors of different types targeting Src, MEK1, B-Raf, JNK, p38, CK1, ATM, CHK1/2
and DNA-PK, and most of them have no effect even at 100 mM. Despite their low sensitivity, some of these inhibitors in the
low micromolar range are able to discriminate between VRK1, VRK2 and B1R. VRK1 is more sensitive to staurosporine, RO-
31-8220 and TDZD8. VRK2 is more sensitive to roscovitine, RO 31–8220, Cdk1 inhibitor, AZD7762, and IC261. Vaccinia virus
B1R is more sensitive to staurosporine, KU55933, and RO 31–8220, but not to IC261. Thus, the three kinases present a
different pattern of sensitivity to kinase inhibitors. This differential response to known inhibitors can provide a structural
framework for VRK1 or VRK2 specific inhibitors with low or no cross-inhibition. The development of highly specific VRK1
inhibitors might be of potential clinical use in those cancers where these kinases identify a clinical subtype with a poorer
prognosis, as is the case of VRK1 in breast cancer.
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Introduction
Most biological processes are regulated by reversible phosphor-
ylation, and kinases play a central role in signal transmission.
Kinases interconnect different signalling pathways in time and
space, and confer flexibility to the regulation and coordination of
multiple biological processes including cell division, apoptosis and
survival among others. Furthermore, alteration in kinase function
is a common underlying process to many pathological situations
including cancer, inflammation, and neurodegeneration. The
elucidation of the human kinome [1] has opened up new
possibilities to characterize and develop strategies to manipulate
these regulatory processes with therapeutic aims [2].
Kinase domains are very suitable for development of specific
inhibitors [3], some of which have already been applied in cancer
treatment, both for tyrosine kinases, such as PDGF/kit with
imatinib in a variety of tumours, or to Ser-Thr kinases such as for
B-Raf in melanomas [4]. Kinase domains in an inactive state are
more structurally diverse than their activated form [2]. However,
the main problem in development of specific inhibitors resides in
the high conservation of the catalytic domain, which reduces the
specificity of most inhibitors by targeting several kinases
simultaneously, which makes them non specific [5,6]. This cross-
inhibition results in a significant promiscuity, which can be the
cause of unexpected side effects in clinical use. The inhibition
promiscuity of a kinase can be predicted based on the conservation
of specific residues within the kinase fold [7].
The VRK kinase family received its name from vaccinia virus
B1R, its unique kinase required for viral replication [8,9]. The
VRK family has a unique ortholog in C. elegans [10] and D.
Melanogaster [11], but is composed of three proteins in mammals
[1], a similar situation to the p53 family that has only one member
in invertebrates and three members in mammals [12], which
reflects the evolution of regulatory mechanisms as the organisms
become more complex. These kinases in the human kinome
belong to a unique and isolated subfamily with only three proteins
VRK that very early, and near the kinases common trunk,
diverged from the branch that much later led to casein kinase I
family [1]. In addition, the VRK proteins have unique
substitutions suggesting they might be pseudokinases [13].
VRK1 and VRK2 are two novel Ser-Thr kinases [14] that have
a common catalytic domain with a fifty-three percent homology
[13,15], and play a role in cell division processes [16–18].
However, VRK1 [13,19–21] and VRK2 [13,22] have been
demonstrated to be catalytically active; while VRK3, the most
divergent of the three, is catalytically inactive [13]. Interestingly,
the kinase activity of VRK1 and VRK2 proteins can be regulated
by allosteric protein-protein interactions; they are both kinase-
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active when bound to RanGTP, and kinase-inactive when bound
to RanGDP [23]. This indicates that these two kinases have two
alternative conformations that can be allosterically regulated [23].
VRK1 is a nuclear kinase [13,19], while VRK2 has two isoforms,
a full-length protein of 508 aminoacids (known as VRK2 and
VRK2A) [13], which is anchored to cytosolic organelle mem-
branes, such as endoplasmic reticulum and mitochondria by its C-
terminal hydrophobic anchoring region [22]; and VRK2B, with
397 aminoacids lacking the C-terminal region and detected both
in cytosol and nucleus, perhaps functionally replacing in some
aspects VRK1 and detected only in some cellular types, like
adenocarcinomas [22]. The conservation in catalytic domain and
different subcellular location indicate that substrate utilization, and
perhaps specificity, might determine signal compartmentalization
and substrate use. The regulation of kinases in time and space is
likely to be an area of intense research in the future [24]. VRK1 is
expressed at high levels in tumours with p53 mutations, such as in
lung cancer [25] and identifies a subgroup of breast cancer with a
poorer prognosis [26,27]. VRK1 is the best characterized protein
of the VRK family regarding its substrates, that include
phosphorylation of p53 in T18 [16,19], c-Jun in S63 and S73
[20], ATF2 in Ser62 and T73 [21], CREB1 in S133 [28] and
histone H3 in T3 and S10 [23,29], this latter modification
regulates methylation and affects chromatin structure. Also,
VRK1 functions as a coordinator of several processes required
for cell division [18], identifies a bad prognosis signature in breast
cancer [26], and specific expression patterns in human tissues,
normal and malignant [30]. Kinase inhibitor screenings have not
yet identified any inhibitor for the VRK family [31], consistent
with its low promiscuity index [7]. Kinases can be discriminated
using a small panel of thirty-eight inhibitors and three hundred
and seventeen kinases as targets, including both tyrosine and
serine-threonine kinases [31].
The atypical structure of VRK proteins determined by specific
aminoacid substitutions [15] makes them suitable targets for
development of specific inhibitors with reduced kinase promiscuity
[7]. Therefore, in this work we have aimed to determine if
catalytically active VRK1 and VRK2 proteins have similar or
different sensitivity to current kinase inhibitors with the aim to
obtain the starting point for future development of kinase specific
inhibitors with limited or no cross-inhibition.
Results
Effect of kinase inhibitors on VRK1 and VRK2 kinase
activity
Despite the similarity in the known in vitro substrates of VRK
proteins, there are some differences in the primary aminoacid
sequence of these kinases, suggesting that a possible way to
functionally discriminate between VRK1 and VRK2 is by their
sensitivity to kinase inhibitors. The VRK2 (VRK2A) crystal
structure indicates that it initially has an active conformation,
which is based on the structure of its kinase domain with its two
lobes presenting a closed conformation, and an activation loop
with a structure that is compatible with kinase activity [15], and
has autophosphorylation activity [13,22]. VRK1, in addition to its
autophosphorylation [19], also phosphorylates histone H3 in Thr3
and Ser10 [23,29]. As an initial approach, the effect of twenty
inhibitors was determined at 100 mM (Fig. 1) and 500 mM (not
shown) in order to identify which ones have some inhibitory effect
on VRK1 or VRK2 kinase activity in the presence of 5 mM ATP,
which permits a higher sensitivity to inhibitors [6], and it is a good
initial screening, since those inhibitors which are effective in the
micromolar range are highly unlikely to be of any use in vivo, since
the intracellular ATP concentration is three orders of magnitude
higher. Among these inhibitors, non-competitive and competitive,
were included two that were detected to bind VRK1 and VRK2
proteins and identified by their induction of a thermal shift, such as
oxindole I and Cdk1 inhibitor [15]. Their inhibitory effects were
tested using an in vitro kinase assay based on autophosphorylation
and histone H3 phosphorylation as substrate. Most of these
inhibitors have little or no effect, but some differences were
noticeable at these high concentrations of inhibitors. VRK1 was
more sensitive to TDZD-8 (Fig. 1A) and VRK2 was more sensitive
to roscovitine and Cdk1 inhibitor (Fig. 1B). The two kinases were
somewhat sensitive to staurosporine, RO 31–8220, AZD7762 and
IC261. Other inhibitors, such as TDZD-20 and oxindole I, were
not able to inhibit either VRK1 or VRK2A. TDZD-8 and
TDZD-20 are non competitive inhibitors. The inhibitor profile of
VRK2B is similar to that of VRK2A (Fig. 1C) and this is consistent
with the complete sequence identity of their common catalytic sites
[22]. The summary of their IC50 values in the presence of 5 mM
ATP is shown in Table 1.
The sensitivity of endogenous VRK1 to the inhibitors identified
in kinase assays with bacterially expressed proteins was also
determined. Endogenous VRK1 protein from 293T cell lysate was
immunoprecipitated and used for kinase assays. The endogenous
protein was sensitive to the same inhibitors as the purified protein
(Fig. 2).
VRK2 is more sensitive than VRK1 to CDK inhibitors
Next we proceeded to analyze in more detail the differential
effect of inhibitors targeting CDK proteins such as Cdk1 Inhibitor,
roscovitine and indirubin-39-monoxime. Indirubin-39-monoxime
had little effect at the high concentration of 100 mM and was not
studied any further (Fig. 1). VRK2 was more sensitive (Fig. 3A) to
Cdk1 inhibitor than VRK1 (not shown), and the kinase activity of
VRK2A was inhibited by fifty percent at 4 mM, determined in the
presence of low ATP, which is similar to that on Cdk1/cyclinB
(5.8 mM) [32]. It is important to note that the effect on both
autophosphorylation and phosphorylation of H3 follow a similar
pattern as shown in the graphs (Fig. 3A). Roscovitine (also known
as CYC202 or Seliciclib), a pan-CDK inhibitor [33] currently in
phase II clinical trials for breast and lung carcinomas [31],
inhibited the activity of VRK2 (Fig. 3B) by fifty percent at
approximately 25 mM, which is higher than the one reported for
inhibition of CDK1/cyclinB, and CDK2/cyclinA (0.7 mM) [34].
VRK1 is less sensitive to roscovitine and was not inhibited at much
higher concentrations, although at 250 mM there was some
noticeable effect (Fig. 3D).
Also, a pan aurora inhibitor, VX-680 [33], in use in clinical
trials [35] was tested without noticeable inhibitory effect on any
VRK protein (Fig. 1).
Effect of PKC inhibitors, RO 31-8220 and staurosporine,
on VRK1 and VRK2 activity
Many inhibitors for PKC proteins have been reported. Among
them are RO 31–8220 and staurosporine, which have been mainly
tested on protein kinase C and can induce apoptosis [36], inhibit
insulin secretion [37] and block PDGF response among many
other effects that can require PKC [38]. The effect of RO 31–
8220 was tested in kinase assays of VRK1 and VRK2A. For both
kinases fifty percent inhibition was similar, between 11 to 34 mM
on H3 phosphorylation or autophosphorylation activity, which is
also much higher than the 5–27 nM reported for PKC isoforms
[39,40], although this inhibitor is known to inhibit multiple kinases
such as MSK1, S6K1 and RSK [41,42]. The effect on both
Inhibitor Profiling of Human VRK Proteins
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autophosphorylation and phosphorylation of H3 followed a similar
pattern (not shown).
In a wide screening, staurosporine appeared to be a potential
inhibitor, although not very efficient, of VRK proteins [31].
VRK1 is more sensitive and fifty percent inhibition was achieved
at 15 mM of staurosporine (Fig. 3C), which is much higher than
the IC50 of 3 nM for PKC [43]. VRK2A was not inhibited by
staurosporine (Fig. 3D). Therefore, staurosporine can discriminate
between VRK1 and VRK2, which is an unexpected observation
since staurosporine is one of the less specific inhibitors known [31].
Effect of inhibitors targeting DNA damage response
kinases: VRK2 is more sensitive than VRK1 to AZD7762
Cellular responses to DNA damage implicate many different
kinases that might be suitable targets for pharmacological
development, since they would sensitize cells to other chemother-
Figure 1. Effect of twenty different inhibitors on the kinase activity of human VRK1 (A), VRK2A (B) and VRK2B (C). The inhibition was
assayed using both autophosphorylation (top), and phosphorylation of histone H3 (bottom), as targets in the kinase assay. All inhibitors were used at
100 mM. In bold are marked those inhibitors that appear to be somewhat more effective in the inhibition of each kinase. The top gels show the in
vitro kinase assay with ATP (5 mM) and [c-32P]-ATP (5 mCi), incubated for 30 minutes at 30uC. The bottom gels show the protein levels detected by
Coomassie blue staining. The assays contain 2 mg of the indicated kinase and 1 mg of recombinant H3. TDZD-8 and TDZD-20 are non-competitive
inhibitors. All the other compounds are competitive inhibitors.
doi:10.1371/journal.pone.0023235.g001
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apeutic drugs. Several inhibitors targeting ATM (KU 55933),
DNA-PK (NU7026, IC86621), and CHK1/2 (AZD7762) were
tested for their effect on VRK1 and VRK2A activity. Only
AZD7762, an inhibitor targeting CHK1 and CHK2, two serine-
threonine kinases involved in DNA damage responses [44], which
is currently used in clinical trials [45], had some effect on VRK
activity. Fifty percent inhibition of both VRK2A autophosphory-
lation and H3 phosphorylation was at 30 mM (not shown). VRK1
was less sensitive than VRK2A, and some inhibition was
detectable at 100 mM (Fig. S1). The other inhibitors, KU 55933,
NU7026 and IC86621 had no noticeable effect on VRK1 or
VRK2A kinase activity (Fig. 1).
Effect of casein kinase and MAPK inhibitors
VRK proteins are the closest group of kinases to casein kinase I
family, from which they diverged very early [1]. IC261 is an
inhibitor that targets several kinases such as CK1 [46–48]. Despite
the closeness between the two VRK proteins, IC261 was more
effective inhibiting VRK2A than VRK1, and VRK2A activity
reached fifty percent inhibition at 10 mM (not shown).
Several inhibitors targeting p38 (SB203580), MEK1 (PD98059),
B-Raf (PLX-4720 and GDC-0879) and JNK (SP600125) were
tested. None of them was able to induce a significant inhibition of
VRK1 or VRK2 activities at 100 mM (Fig. 1A,B). PP1, an inhibitor
that targets several kinases such as Src, Lck and CK1d [33], had no
effect on VRK1 or VRK2 activities at 100 mM (Fig. 1A,B).
Non-competitive inhibitors: VRK1 is more sensitive than
VRK2 to TDZD-8
Heterocyclic thiadiazolidinones, TDZD-8 and TDZD-20, are
two non-competitive inhibitors that were developed to inhibit
Table 1. VRK1 and VRK2A sensitivity and IC50 values of serine-threonine kinase inhibitors.
IC50 (mM)
GST-VRK1 GST-VRK2A
Auto- phosphorylation H3 phosphorylation Auto-phosphorylation H3 phosphorylation
Roscovitine No inhibition 25.761.23 55.3461.6
RO 31–8220 11.1161.16 34.3961.05 31.7761.15 33.6361.04
Cdk1 Inhibitor No inhibition 11.261.33 10.7761.29
Oxindole I No inhibition No inhibition
Staurosporine 15.2761.10 36.8761.09 No inhibition
KU55933 No inhibition No inhibition
NU7026 No inhibition No inhibition
IC86621 No inhibition No inhibition
AZD7768 No inhibition 39.9861.07 24.3861.07
VX-680 No inhibition No inhibition
PLX-4720 No inhibition No inhibition
GDC-0879 No inhibition No inhibition
PD98059 No inhibition No inhibition
IC261 121.3961.05 55.9361.04 11.0961.10 14.7161.13
PP1 No inhibition No inhibition
Indirubin No inhibition 50.6661.23 57.2361.17
SB203580 No inhibition No inhibition
SP600125 No inhibition 27.5961.09 11.1361.21
TDZD-8 Inhibition at 7.5 mM No inhibition
TDZD-20 No inhibition No inhibition
The IC50 values were calculated in the presence of 5 mM ATP. The individual points are the average from three experiments. The linear regression and the standard
deviation were calculated with the SPSS program for VRK1 (Fig. S3) and VRK2A (Fig. S4). All values are mM. No inhibition is lack of effect at 100 mM.
doi:10.1371/journal.pone.0023235.t001
Figure 2. Inhibition of human VRK1 expressed in 293T cells. The
endogenous VRK1 protein, from HEK 293T cells, was immunoprecipitated
and used for an in vitro kinase assay. The relative inhibition was
determined at a concentration of 75 mM for those inhibitors previously
identified by testing them in bacterially expressed VRK1. Endogenous
VRK1 protein was immunoprecipitated with 1F6 mAb, anti-VRK1, as control
an anti-HA mAb was used. The VRK1 immunoprecipitate was incubated in
the presence of 75 mM inhibitor, 5 mM ATP and 5 mCi of [c32P]ATP.
doi:10.1371/journal.pone.0023235.g002
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GSK3b [49], and in clinical trials for treatment of Alzheimer’s
disease [50]. VRK1 was insensitive to this inhibitor, but in a very
short concentration range its effect changed and VRK1 activity was
fully inhibited. There was no significant inhibition of VRK1 activity
at 5 mM, but it was almost completely inhibited at 7.5 mM, both in
autophosphorylation or H3 phosphorylation (Fig. S2A). The related
TDZD-20 inhibitor had no effect at similar concentrations (Fig.
S2B). VRK2A was insensitive to TDZD-8 at 500 mM (not shown)
and it was also insensitive to TDZD-20 at 100 mM (Fig. 1B).
Inhibition of vaccinia virus B1R kinase
Vaccinia virus, and related poxviruses, has a unique kinase in
their genome that is required for viral DNA replication [8,9]. This
kinase, B1R, gave the name to mammalian VRK proteins, but
their homology is reduced to forty percent [13], and it presents
differences in its phosphorylation activity compared to the human
VRK proteins. B1R has a reduced autophosphorylation, and
phosphorylates p53 in multiple residues [51], whereas VRK1
[16,19] and VRK2 [22] phosphorylate p53 in a unique residue,
and they also have a strong autophosphorylation activity.
Therefore, it was tested the sensitivity of B1R to the panel of
twenty kinase inhibitors in a kinase assay using p53 and histone H3
as substrates (Fig. 4) 5 in the presence of ATP at 5 mM. B1R was
sensitive to staurosporine, KU55933 and RO 31–8220. This result
has some overlap, but is not identical, to VRK1 or VRK2
inhibition patterns.
Figure 3. Differential effect of CDK inhibitors on VRK1 and VRK2 and discrimination between VRK1 and VRK2 by staurosporine.
A. Inhibition of VRK2 by Cdk1 inhibitor. Quantification of the inhibition achieved on autophosphorylation and histone H3 phosphorylation is shown
in the graph below. Quantification was performed in the linear response range. B. Inhibition of VRK2A by roscovitine, an inhibitor in phase II clinical
trials. Quantification of the inhibition achieved on autophosphorylation and histone H3 phosphorylation is shown in the graph below. C. Inhibition of
VRK1 activity by staurosporine. At the bottom the quantification in the linear response range is shown. D. Lack of effect of staurosporine on VRK2A
activity. At the bottom the quantification in the linear response range is shown.
doi:10.1371/journal.pone.0023235.g003
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Discussion
One of the main implications of VRK proteins is their potential
utilization for developing specific inhibitors that may be used in
oncologic treatments. But a main problem with current inhibitors is
that they usually affect several related kinases simultaneously,
although there might be some differences in affinity [5,6,33]. In
practice, this means that the clinical use of inhibitors affecting
several kinases might present a significant risk of uncontrolled side
effects. An alternative approach to identify kinases for specific
targeting is the use of kinase specific siRNA [52]. VRK proteins
were not identified in an extensive kinase siRNA screening [53],
probably because the effect was studied at forty-eight hours, which is
not suitable for very stable proteins with half-life of four to six days
such as VRK1 [54]. However, kinases knockdown has a limitation
in case of very stable proteins, as VRKs, since in RNA interference
experiments the observation time allows the reduction in RNA, but
not in the protein level [53]. The knockdown of VRK1 and VRK2
has already provided indication of processes that might be
selectively affected by their specific inhibition. Knockdown of
VRK1 results in a block in cell cycle progression before the
restriction point in G1 [16,54], thus it can be used in pathologies
where proliferation is part of its pathogenesis. In the case of VRK2,
its knockdown affects signalling by MAPK, since VRK2 modulates
signal transmission by direct interaction with scaffold proteins, such
as JIP1 affecting the response to hypoxia [55] or cytokines [56], and
KSR1 affecting oncogene signalling [57].
Based on their structural differences, VRK1 and VRK2 kinases
are predicted to be proteins with a very low promiscuity index and
be insensitive to current kinase inhibitors [5,7,31]. The pattern of
VRK inhibitors detected in this work confirms this prediction and
presents two main characteristics. First of all, human VRK1 and
VRK2, as well as vaccinia B1R, are in general very insensitive to
the panel of inhibitors tested in the current study that target a large
variety of human kinases with an IC50 in the nanomolar range in
most cases. Most of them have little, if any, effect on VRK kinases
even at a high concentration, which makes them unsuitable for in
vivo use. The second characteristic is that the inhibition detected
for some compounds does not bear any relation to a particular
subtype of kinases.
Among the poor inhibitors identified, there is a clear differential
pattern between VRK1 and VRK2. VRK1 is more sensitive to
staurosporine and RO 31–8220, two inhibitors of PKC; while
VRK2 is more sensitive to Cdk1 inhibitor and roscovitine, two
Cdk1 (cdc2) inhibitors. Interestingly, Cdk1 inhibitor has been
shown to equally interact with both kinases [15], but only VRK2
activity was inhibited. For all inhibitors, their sensitivity is reduced
by three orders of magnitude when compared with their
preferentially targeted kinases. Another inhibitor for which VRK
proteins show some sensitivity is AZD7762 that targets CHK1 and
CHK2 with much higher affinity. Although VRK2, and less
efficiently VRK1, are inhibited by AZD7762, the IC50 is more
than five orders of magnitude higher than that required for CHK1
and CHK2 inhibition [44,58]. Thus, IC261 inhibits CK1 at 6
micromolar, similar to the inhibition of VRK2 [5,33], but has no
effect on VRK1 activity. In addition, VRK1, but not VRK2, is
sensitive to a non-competitive inhibitor TDZD-8, which targets
GSK3. Neither VRK1 nor VRK2 respond to current inhibitors of
B-Raf (wild-type or mutant V600E), ATM, DNA-PK, MEK1 and
aurora kinases. The observation that even the best inhibitors only
have some effect at low micromolar concentrations, when they are
assayed in the presence of 5 mM ATP, indicates that both substrate
and inhibitor have to be at similar concentrations in order to
detected an inhibitory effect, and this means that in vivo the
inhibitor is not likely to function since intracellular ATP
concentration is three orders of magnitude higher.
These data suggest that a comparative analysis of VRK2
structure with that of those inhibitors to which they are somewhat
sensitive might provide enough structural clues that can be used to
start modelling VRK1 and VRK2 specific inhibitors with a
reduced promiscuity. The differences detected in the kinase
domain of VRK proteins indicate that they might be very suitable
for designing specific inhibitors, because the likelihood of cross-
inhibition of other kinases is very low, as suggested by the
promiscuity score in which VRK1 and VRK2 are the kinases with
the likelihood of having the most specific inhibitors [7]. This
prediction was also confirmed in a different experimental
approach based on the determination on the kinase specificity of
current inhibitors [31]. VRK1 has been identified as a drugable
kinase in rhabdomyosarcoma [59] and breast cancer [60].
Figure 4. Inhibition of vaccinia virus B1R kinase. Phosphorylation assays were performed using 1 mg of purified GST-p53 or Histone H3 as
substrates. Quantification was performed in the linear response range.
doi:10.1371/journal.pone.0023235.g004
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The pattern of VRK1 and VRK2 inhibition suggests that they
might be structurally closer to cdk1 than any other kinases, but
even so, they maintain large differences. However, the high
concentrations needed to achieve some inhibition means that none
of the inhibitors tested can be used to inhibit VRK proteins in cell
based assays, since they will also affect several other kinases.
Kinase activation implies a conformational change involving the
activation loop that has a DFG motif in an out (inactive) or in
(active) state [61,62]. These alternative conformations might affect
the kinase response to inhibitors. In the DFG out or inactive state,
the kinase might bind and prevent the activating conformational
change, rather than displacing ATP in case of competitive
inhibitors. Thus, depending on the conformation the effect may
vary. On the other hand, in the active state, competitive inhibitors
will displace the nucleotide. In vivo the situation is likely to be a
mixture of different situations. VRK1 inhibition by TDZD-8, a non
competitive inhibitor of GSK3b [49], might be a particular case.
The TDZD-8 effect on VRK1 activity seems to be an all or none
effect at a specific concentration. This might reflect the switch
between two alternative VRK1 conformations when the inhibitor
reaches a critical threshold concentration. It would be interesting to
know if TDZD-8 is acting by maintaining a loop out conformation
for its activation loop [61] that has some peculiarities [15,62].
The identification and validation of specific inhibitors for
human VRK proteins and vaccinia B1R have the potential of
clinical applications. In this context, development of specific
inhibitors for VRK1 and VRK2 is a real possibility because they
are likely to be highly specific. Since these kinases have been
implicated in response to growth factors and in DNA damage
response, their inhibitors can make cells more sensitive to current
chemotherapeutic drugs or irradiation, reducing the toxicity
associated with them, since kinase inhibitors have shown to be
well tolerated by patients. Use of kinase inhibitors for treatment of
acute infection by poxviruses, such as smallpox, might be an
alternative therapy for acute viral infection by reducing viral
replication. The development of such specific inhibitors is a real
possibility that needs to be pursued once the structure of these
proteins and lead compounds become available.
Materials and Methods
Plasmids and expression of proteins
Human VRK1 was expressed from plasmid pGEX4T-VRK1 [19]
and purified using Glutathion-Sepharose (GE Healthcare). VRK2A
and VRK2B proteins were expressed from plasmids pGEX4T-
VRK2A and pGEX4T-VRK2B respectively in BL21 E. coli strain
[22]. Vaccinia virus B1R was expressed from plasmid pGEX-B1R
[51]. The GST-p53 has been described previously [19,51]. GST
fusion proteins were eluted from the corresponding resin with
reduced glutathione [22]. Protein purification was checked in a 10%
PAGE [63]. Endogenous VRK1 protein from 293T cells was
immunoprecipitated with an anti-VRK1 monoclonal antibody (1F6)
[63], and the immunoprecipitate was used for an in vitro kinase assay.
Reagents
All reagents were of analytical grade from Sigma. The
nucleotide [32P-c] ATP was from PerkinElmer/NEN. Recombi-
nant histone H3 was from Upstate Biotechnology-Millipore (Lake
Placid, NY).
In vitro kinase assay
Kinase assays were performed using both purified proteins and
histone H3, or immunoprecipitated candidate proteins. VRK
kinase activity was determined by assaying protein phosphorylation
in a final volume of 30 mL containing kinase buffer (20 mM Tris-
HCl pH 7.5, 5 mM MgCl2, 0.5 mM DTT and 150 mM KCl),
5 mM ATP and 5 mCi of [c32P]ATP with 2 mg of GST-VRK1,
GST-VRK2A or GST-VRK2B protein and the indicated concen-
trations of kinase inhibitors. In this work we used bacterially
expressed VRK1, as well as immunoprecipitated endogenous
VRK1, and 1 mg of recombinant histone H3 was used as a
substrate. The kinase, substrate H3 and inhibitor were pre-
incubated for 10 min at 30uC before adding ATP. In the case of
vaccinia B1R protein that has a low autophosphorylation activity,
1 mg of GST-p53 was used as substrate. Then, the reactions were
performed at 30uC for 30 min in a Thermomixer (Eppendorf) and
stopped by boiling in Laemmli buffer. Reactions and quantifications
were performed in their linear response range. The proteins in the
assay were analyzed by electrophoresis in 12.5% SDS-polyacrila-
mide gels. The gels were stained with Coomassie Blue or proteins
were transferred to PVDF membrane and the incorporated activity
was measured. The SPSS program v.19 (Inc. IBM Company) was
used for linear regression analysis and calculation of IC50 values.
Kinase inhibitors
Roscovitine; Cdk1 Inhibitor; Oxindole I; IC261/SU 5607, an
inhibitor of CK1; PP1, an inhibitor of LCK and FYN; PD 98059,
a selective, reversible inhibitor of MEK; and SP600125 inhibitor
of JNK, were from Calbiochem-Merck (Darmstadt, Germany).
NU7026, an inhibitor of DNA-PK in a ATP-competitive manner;
IC86621, a DNA-PK catalytic subunit inhibitor; SB 203580,
inhibitor of p38; Indirubin-39-monoxime, an inhibitor of CDK;
Staurosporine, a potent inhibitor of PKC; and RO 31–8220 were
from Sigma-Aldrich (St. Louis, MO). KU 55933 a selective and
competitive ATM kinase inhibitor that functions as a radio- and
chemosensitizer for cancer treatment, was from Tocris Bioscience
(Bristol, UK). VX-680, an Aurora kinases inhibitor; AZD7762,
inhibitor of CHK1/2; PLX-4720 and GDC-0879, B-raf1
inhibitors were from Selleck Chemicals (Houston, TX). Non
competitive inhibitors: TDZD-8 (GSK-3b Inhibitor I), and
TDZD-20 (GSK-3 Inhibitor XVII) were from Calbiochem-Merck
(Darmstadt, Germany). Inhibitors are summarized in Table S1.
Supporting Information
Figure S1 Effect of AZD7762, a CHK1/2 inhibitor on
VRK1 (A) and VRK2 (B). At the bottom the quantification in
the linear response range is shown. VRK2A is more sensitive than
VRK1 to this inhibitor independently of the assay type. AZD7762
is currently in phase II clinical trials.
(TIF)
Figure S2 Effect of TDZD-8 and TDZD-20 non-competitive
inhibitors on VRK1 and VRK2. A. Effect of TDZD-8 on VRK1
in autophosphorylation and H3 phosphorylation assays. At the bottom
the quantification of the blots is shown. B. Effect of TDZD-20 on
VRK1 autophosphorylation and H3 phosphorylation. C. Effect of
TDZD-8 on VRK2A autophosphorylation and H3 phosphorylation.
(TIF)
Figure S3 Determination of IC50 values for several
inhibitors in autophosphorylation and histone H3 trans-
phosphorylation assays of VRK1. The values from three
experiments using inhibitors to which VRK1 is sensitive were used
for calculation of the IC50 value. Linear regression analysis was
performed and the R2 value calculated using the SPSS program.
(TIF)
Figure S4 Determination of IC50 values for several
inhibitors in autophosphorylation and histone H3 trans-
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phosphorylation assays of VRK2A. The values from three
experiments using inhibitors to which VRK2A is sensitive were used
for calculation of the IC50 value. Linear regression analysis was
performed and the R2 value calculated using the SPSS program.
(TIF)
Table S1 Inhibitors of serine-threonine kinases
(DOC)
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